Inventor
MUNDIGL OLAF
DE36 patents
⚠️ This page may combine multiple inventors who share the name “MUNDIGL OLAF”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
HOFFMANN LA ROCHE
29 patentsUS9290567B2Mar 22, 2016
Use of an anti-Tau pS422 antibody for the treatment of brain diseases
HOFFMANN LA ROCHE25 citations92
US7572897B2Aug 11, 2009
Antibodies against insulin-like growth factor I receptor and uses thereof
HOFFMANN LA ROCHE19 citations92
US7098241B2Aug 29, 2006
Thiophene hydroxamic acid derivatives
HOFFMANN LA ROCHE27 citations92
US6627439B2Sep 30, 2003
Antibodies against SEMP1(p23)
HOFFMANN LA ROCHE26 citations90
US10822402B2Nov 3, 2020
Humanized anti-tau(pS422) antibodies and methods of use
HOFFMANN LA ROCHE4 citations83
US9862763B2Jan 9, 2018
Humanized anti-tau(pS422) antibodies and methods of use
HOFFMANN LA ROCHE4 citations83
US7378503B2May 27, 2008
Antibodies against insulin-like growth factor 1 receptor and uses thereof
HOFFMANN LA ROCHE13 citations83
US9890209B2Feb 13, 2018
Anti-alpha-synuclein antibodies and methods of use
HOFFMANN LA ROCHE10 citations82
US9670274B2Jun 6, 2017
Anti-alpha-synuclein antibodies and methods of use
HOFFMANN LA ROCHE6 citations82
US9493553B2Nov 15, 2016
Anti-alpha-synuclein antibodies and methods of use
HOFFMANN LA ROCHE8 citations82
US11273223B2Mar 15, 2022
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
HOFFMANN LA ROCHE1 citations73
US10806795B2Oct 20, 2020
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
HOFFMANN LA ROCHE3 citations73
US10561737B2Feb 18, 2020
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
HOFFMANN LA ROCHE4 citations73
US7579157B2Aug 25, 2009
Antibody selection method against IGF-IR
HOFFMANN LA ROCHE7 citations73
US6800638B2Oct 5, 2004
Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors
HOFFMANN LA ROCHE10 citations73
US10465000B2Nov 5, 2019
Humanized anti-Tau(pS422) antibodies and methods of use
HOFFMANN LA ROCHE2 citations72
US9562091B2Feb 7, 2017
Humanized anti-Tau(pS422) antibodies and methods of use
HOFFMANN LA ROCHE4 citations72
US10730938B2Aug 4, 2020
Bispecific antibodies and methods of use in ophthalmology
HOFFMANN LA ROCHE3 citations71
US10344085B2Jul 9, 2019
Anti-IL-1beta antibodies
HOFFMANN LA ROCHE5 citations71
US10087246B2Oct 2, 2018
Anti-PDGF-B antibodies and methods of use
HOFFMANN LA ROCHE2 citations71
US12297263B2May 13, 2025
Humanized anti-Tau(PS422) antibodies and methods of use
HOFFMANN LA ROCHE0 citations62
US11572404B2Feb 7, 2023
Humanized anti-Tau(pS422) antibodies and methods of use
HOFFMANN LA ROCHE0 citations62
US7091229B2Aug 15, 2006
Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors
HOFFMANN LA ROCHE4 citations62
US11866490B2Jan 9, 2024
Antibody that binds to VEGF and IL-1beta and methods of use
HOFFMANN LA ROCHE0 citations60
US11130804B2Sep 28, 2021
Antibody that binds to VEGF and IL-1beta and methods of use
HOFFMANN LA ROCHE0 citations60
US10647761B2May 12, 2020
Anti-alpha-synuclein antibodies and methods of use
HOFFMANN LA ROCHE0 citations51
US10316082B2Jun 11, 2019
Anti-alpha-synuclein antibodies and methods of use
HOFFMANN LA ROCHE0 citations51
US9187563B2Nov 17, 2015
Anti-human EPO receptor antibodies and methods of use
HOFFMANN LA ROCHE0 citations51
US9574016B2Feb 21, 2017
Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent
HOFFMANN LA ROCHE0 citations50